What is the 13F Pro Quality Score for NEUP?

13F Pro ranks Neuphoria Therapeutics Inc. (NEUP) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NEUP's current score at https://13fpro.ai/research/NEUP (free sign-up required for the full ranking).

Where does 13F Pro source NEUP data?

All Neuphoria Therapeutics Inc. fundamentals and ownership data come directly from SEC EDGAR. Neuphoria Therapeutics Inc. files with the SEC under CIK 1191070. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NEUP in?

Neuphoria Therapeutics Inc. (NEUP) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is NEUP research updated on 13F Pro?

NEUP's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Neuphoria Therapeutics Inc.(NEUP)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1191070 NEUP stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $15.6M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

NEUP Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Neuphoria Therapeutics Inc. (NEUP), a Healthcare sector company. NEUP is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $15.6m in revenue. Based on the latest XBRL financial filings (Q3 2026), Neuphoria Therapeutics Inc. reports net income of $-505.1K, free cash flow of $-3.3M. Top institutional holders of NEUP by reported 13-F value include Lynx1 Capital Management, AdvisorShares Investments, Shay Capital, based on the most recent SEC filings. NEUP trades on the Nasdaq exchange and files with the SEC under CIK 1191070. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NEUP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Neuphoria Therapeutics Inc. directly from SEC EDGAR.

Net Income

Q3 2026

$-505.1K

Free Cash Flow

Q3 2026

$-3.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2024

FY22 $263.6KFY23 $22.0KFY24 —

Net Income

+27.5% YoY

$-15.5MFY 2024

FY22 —FY23 $-21.4MFY24 $-15.5M

Operating Income

+18.6% YoY

$-17.9MFY 2024

FY22 —FY23 $-22.0MFY24 $-17.9M

EPS (Diluted)

$-0.01FY 2024

FY22 —FY23 $0.00FY24 $-0.01

Total Assets

-3.2% YoY

$27.6MFY 2024

FY22 $65.3MFY23 $28.6MFY24 $27.6M

Op. Cash Flow

-0.3% YoY

$-14.7MFY 2024

FY22 —FY23 $-14.6MFY24 $-14.7M

Metric	FY 2024	FY 2023	FY 2022
Revenue	—	$22.0K -91.6%	$263.6K
Net Income	$-15.5M +27.5%	$-21.4M	—
Operating Income	$-17.9M +18.6%	$-22.0M	—
EPS (Diluted)	$-0.01	$0.00	—
Total Assets	$27.6M -3.2%	$28.6M -56.3%	$65.3M
Operating Cash Flow	$-14.7M -0.3%	$-14.6M	—

AI Insight: NEUP Financial Trends

Neuphoria's revenue collapsed post-Q1 2025, with operating cash flow swinging negative and equity volatility suggesting dilutive financing.

• Revenue vanished after Q1 2025 ($15M), with no disclosed sales in subsequent quarters through Q1 2026.

• Operating cash flow deteriorated from $14M in Q1 2025 to negative $4M–$6M range in Q2–Q4 2025.

• Equity swung from $26M (Q1 2025) to $13M (Q3 2025) low, then rebounded to $30M (Q4 2025), signaling dilution or restructuring.

⚠ Operating income turned negative $4M–$6M from Q2 2025 onward despite Q1 2025 profitability — structural cost issue.

⚠ Q4 2025 showed $2M net income but negative $4M operating income and negative $6M cash flow — likely non-cash gain or financing.

AI Insight: NEUP Ratio Trends

Data too sparse to establish meaningful trends; only 3 quarters have material profitability metrics, with extreme volatility masking underlying business health.

• Q1 2025 showed exceptional profitability: OpMargin 96.1%, NPM 110.4%. Both metrics vanished by Q2 2025, suggesting one-time items or data irregularities.

• Q4 2025 ROE recovered to 25.1% and ROA to 20.4%, but ROIC deeply negative at -54.7%, indicating capital destruction despite earnings.

⚠ Severe metric discontinuity across consecutive quarters—most data absent—limits visibility into normalized profitability and capital efficiency trends.

⚠ ROIC collapse to -54.7% in Q4 2025 signals potential acquisition integration costs, write-downs, or asset impairments warrant investigation.

Get alerted when NEUP's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Neuphoria Therapeutics Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NEUP

Lynx1 Capital Management LP
$3.6M875,328 sh
AdvisorShares Investments LLC
$632.3K155,367 sh
Shay Capital LLC
$614.6K151,010 sh
BALYASNY ASSET MANAGEMENT L.P.
$578.7K142,183 sh
Squadron Capital Management LLC
$312.3K76,728 sh
GEODE CAPITAL MANAGEMENT, LLC
$211.7K52,007 sh
Ikarian Capital, LLC
$193.1K47,443 sh
ADAR1 Capital Management, LLC
$122.1K30,000 sh
CITADEL ADVISORS LLC
$78.7K19,331 sh
BOOTHBAY FUND MANAGEMENT, LLC
$57.0K14,000 sh

Fund	Value	Shares
Lynx1 Capital Management LP	$3.6M	875,328
AdvisorShares Investments LLC	$632.3K	155,367
Shay Capital LLC	$614.6K	151,010
BALYASNY ASSET MANAGEMENT L.P.	$578.7K	142,183
Squadron Capital Management LLC	$312.3K	76,728
GEODE CAPITAL MANAGEMENT, LLC	$211.7K	52,007
Ikarian Capital, LLC	$193.1K	47,443
ADAR1 Capital Management, LLC	$122.1K	30,000
CITADEL ADVISORS LLC	$78.7K	19,331
BOOTHBAY FUND MANAGEMENT, LLC	$57.0K	14,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NEUP on your watchlist

Track score changes the day Neuphoria Therapeutics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NEUP a good stock to buy?

13F Pro's AI-powered analysis of Neuphoria Therapeutics Inc. (NEUP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NEUP are available on the NEUP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own NEUP?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NEUP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Neuphoria Therapeutics Inc.'s investment landscape.